CSF biomarkers for Alzheimer's disease diagnosis

International Journal of Alzheimer's Disease

Volumn , Issue , 2010, Pages

  Maji, Samir K ^a   Anoop, A ^a   Singh, Pradeep K ^a   Jacob, Reeba S ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY BOMBAY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; ALPHA 2 MACROGLOBULIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BIOLOGICAL MARKER; COMPLEMENT FACTOR H; INTERLEUKIN 6; REACTIVE OXYGEN METABOLITE; TAU PROTEIN;

ALZHEIMER DISEASE; BRAIN SIZE; CEREBROSPINAL FLUID; COGNITIVE DEFECT; COMPUTER ASSISTED TOMOGRAPHY; DEMENTIA; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; EARLY DIAGNOSIS; FRONTOTEMPORAL DEMENTIA; HUMAN; LUMBAR PUNCTURE; MILD COGNITIVE IMPAIRMENT; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PAIRED HELICAL FILAMENT; PLASMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY;

EID: 77955953955     PISSN: None     EISSN: 20900252     Source Type: Journal    
DOI: 10.4061/2010/606802     Document Type: Review

References (139)

1. Hebert L. E., Scherr P. A., Bienias J. L., Bennett D. A., Evans D. A., Alzheimer disease in the US population: prevalence estimates using the 2000 census Archives of Neurology 2003 60 8 1119 1122
2. Brookmeyer R., Johnson E., Ziegler-Graham K., Arrighi H. M., Forecasting the global burden of Alzheimer's disease Alzheimer's and Dementia 2007 3 3 186 191
3. Selkoe D. J., Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases Nature Cell Biology 2004 6 11 1054 1061
4. Lazo N.D., Maji S. K., Fradinger E. A., Sipe J. D., The amyloid beta protein Amyloid Protein-The Beta Sheet Conformation and Disease 2005 Weinheim, Germany Wiley-VCH Publishers 385 491
5. Grundke-Iqbal I., Iqbal K., Tung Y.-C., Abnormal phosphorylation of the microtubule-associated protein (tau) in Alzheimer cytoskeletal pathology Proceedings of the National Academy of Sciences of the United States of America 1986 83 13 44913 4917
6. Grundke-Iqbal I., Iqbal K., Quinlan M., Microtubule-associated protein tau. A component of Alzheimer paired helical filaments The Journal of Biological Chemistry 1986 261 13 6084 6089
7. Morris J. C., The challenge of characterizing normal brain aging in relation to Alzheimer's disease Neurobiology of Aging 1997 18 4 388 389
8. Morris J. C., Price J. L., Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease Journal of Molecular Neuroscience 2001 17 2 101 118
9. Perrin R. J., Fagan A. M., Holtzman D. M., Multimodal techniques for diagnosis and prognosis of Alzheimer's disease Nature 2009 461 7266 916 922
10. Blennow K., Hampel H., Weiner M., Zetterberg H., Cerebrospinal fluid and plasma biomarkers in Alzheimer disease Nature Reviews Neurology 2010 6 3 131 144
11. Clark C. M., Davatzikos C., Borthakur A., Newberg A., Leight S., Lee V. M.-Y., Trojanowski J. Q., Biomarkers for early detection of Alzheimer pathology NeuroSignals 2007 16 1 11 18
12. Killiany R. J., Gomez-Isla T., Moss M., Kikinis R., Sandor T., Jolesz F., Tanzi R., Jones K., Hyman B. T., Albert M. S., Use of structural magnetic resonance imaging to predict who will get Alzheimers disease Annals of Neurology 2000 47 4 430 439
13. Moulin C. J. A., Laine M., Rinne J. O., Kaasinen V., Sipil H., Hiltunen J., Kangasmki A., Brain function during multi-trial learning in mild cognitive impairment: a PET activation study Brain Research 2007 1136 1 132 141
14. Mathis C. A., Wang Y., Holt D. P., Huang G.-F., Debnath M. L., Klunk W. E., Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents Journal of Medicinal Chemistry 2003 46 13 2740 2754
15. Hye A., Lynham S., Thambisetty M., Causevic M., Campbell J., Byers H. L., Hooper C., Rijsdijk F., Tabrizi S. J., Banner S., Shaw C. E., Foy C., Poppe M., Archer N., Hamilton G., Powell J., Brown R. G., Sham P., Ward M., Lovestone S., Proteome-based plasma biomarkers for Alzheimer's disease Brain 2006 129 11 3042 3050
16. Kuo Y.-M., Kokjohn T. A., Kalback W., Luehrs D., Galasko D. R., Chevallier N., Koo E. H., Emmerling M. R., Roher A. E., Amyloid- peptides interact with plasma proteins and erythrocytes: implications for their quantitation in plasma Biochemical and Biophysical Research Communications 2000 268 3 750 756
17. Fukumoto H., Tennis M., Locascio J. J., Hyman B. T., Growdon J. H., Irizarry M. C., Age but not diagnosis is the main predictor of plasma amyloid -protein levels Archives of Neurology 2003 60 7 958 964
18. Maddalena A., Papassotiropoulos A., Mller-Tillmanns B., Jung H. H., Hegi T., Nitsch R. M., Hock C., Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to -amyloid peptide42 Archives of Neurology 2003 60 9 1202 1206
19. Aluise C. D., Sowell R. A., Butterfield D. A., Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer's disease Biochimica et Biophysica Acta 2008 1782 10 549 558
20. Kantarci K., Jack C. R. Jr., Neuroimaging in Alzheimer disease: an evidence-based review Neuroimaging Clinics of North America 2003 13 2 197 209
21. Thal L. J., Kantarci K., Reiman E. M., Klunk W. E., Weiner M. W., Zetterberg H., Galasko D., Pratic D., Griffin S., Schenk D., Siemers E., The role of biomarkers in clinical trials for Alzheimer disease Alzheimer Disease and Associated Disorders 2006 20 1 6 15
22. Raichle M. E., Mintun M. A., Brain work and brain imaging Annual Review of Neuroscience 2006 29 449 476
23. Frisoni G. B., Structural imaging in the clinical diagnosis of Alzheimer's disease: problems and tools Journal of Neurology Neurosurgery and Psychiatry 2001 70 6 711 718
24. Scheltens P., Fox N., Barkhof F., De Carli C., Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion Lancet Neurology 2002 1 1 13 21
25. Barnes J., Whitwell J. L., Frost C., Josephs K. A., Rossor M., Fox N. C., Measurements of the amygdala and hippocampus in pathologically confirmed Alzheimer disease and frontotemporal lobar degeneration Archives of Neurology 2006 63 10 1434 1439
26. Barnes J., Godbolt A. K., Frost C., Boyes R. G., Jones B. F., Scahill R. I., Rossor M. N., Fox N. C., Atrophy rates of the cingulate gyrus and hippocampus in AD and FTLD Neurobiology of Aging 2007 28 1 20 28
27. Whitwell J. L., Jack C. R. Jr., Comparisons between Alzheimer disease, frontotemporal lobar degeneration, and normal aging with brain mapping Topics in Magnetic Resonance Imaging 2005 16 6 409 425
28. Becker J. T., Mintun M. A., Aleva K., Wiseman M. B., Nichols T., DeKosky S. T., Compensatory reallocation of brain resources supporting verbal episodic memory in Alzheimer's disease Neurology 1996 46 3 692 700
29. Grady C. L., Furey M. L., Pietrini P., Horwitz B., Rapoport S. I., Altered brain functional connectivity and impaired short-term memory in Alzheimer's disease Brain 2001 124 4 739 756
30. Woodard J. L., Grafton S. T., Votaw J. R., Green R. C., Dobraski M. E., Hoffman J. M., Compensatory recruitment of neural resources during overt rehearsal of word lists in Alzheimer's disease Neuropsychology 1998 12 4 491 504
31. Mintun M. A., Larossa G. N., Sheline Y. I., Dence C. S., Lee S. Y., MacH R. H., Klunk W. E., Mathis C. A., Dekosky S. T., Morris J. C., [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease Neurology 2006 67 3 446 452
32. Klunk W. E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D. P., Bergstrm M., Savitcheva I., Huang G.-F., Estrada S., Ausn B., Debnath M. L., Barletta J., Price J. C., Sandell J., Lopresti B. J., Wall A., Koivisto P., Antoni G., Mathis C. A., Lngstrm B., Imaging brain amyloid in alzheimer's disease with pittsburgh compound-B Annals of Neurology 2004 55 3 306 319
33. Fagan A. M., Mintun M. A., Mach R. H., Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans Annals of Neurology 2006 59 3 512 519
34. Fagan A. M., Roe C. M., Xiong C., Mintun M. A., Morris J. C., Holtzman D. M., Cerebrospinal fluid tau/ -amyloid 42 ratio as a prediction of cognitive decline in nondemented older adults Archives of Neurology 2007 64 3 343 349
35. Forsberg A., Engler H., Almkvist O., Blomquist G., Hagman G., Wall A., Ringheim A., Lngstrm B., Nordberg A., PET imaging of amyloid deposition in patients with mild cognitive impairment Neurobiology of Aging 2008 29 10 1456 1465
36. Motter R., Vigopelfrey C., Kholodenko D., Reduction of beta-amyloid peptide(42), in the cerebrospinal fluid of patients with Alzheimers disease Annals of Neurology 1995 38 4 643 648
37. Samuels S. C., Silverman J. M., Marin D. B., Peskind E. R., Younki S. G., Greenberg D. A., Schnur E., Santoro J., Davis K. L., CSF beta-amyloid, cognition, and APOE genotype in Alzheimer's disease Neurology 1999 52 3 547 551
38. Edison P., Archer H. A., Gerhard A., Hinz R., Pavese N., Turkheimer F. E., Hammers A., Tai Y. F., Fox N., Kennedy A., Rossor M., Brooks D. J., Microglia, amyloid, and cognition in Alzheimer's disease: an [11C](R)PK11195-PET and [11C]PIB-PET study Neurobiology of Disease 2008 32 3 412 419
39. Nakamura S., Kawamata T., Akiguchi I., Kameyama M., Nakamura N., Kimura H., Expression of monoamine oxidase B activity in astrocytes of senile plaques Acta Neuropathologica 1990 80 4 419 425
40. Hirvonen J., Kailajrvi M., Haltia T., Koskimies S., Ngren K., Virsu P., Oikonen V., Sipil H., Ruokoniemi P., Virtanen K., Scheinin M., Rinne J. O., Assessment of MAO-B occupancy in the brain with PET and 11 C-L-deprenyl-D 2: a dose-finding study with a novel MAO-B inhibitor, EVT 301 Clinical Pharmacology and Therapeutics 2009 85 5 506 512
41. Blennow K., Hampel H., CSF markers for incipient Alzheimer's disease Lancet Neurology 2003 2 10 605 613
42. Bauer J., Strauss S., Schreiter-Gasser U., Ganter U., Schlegel P., Witt I., Yolk B., Berger M., Interleukin-6 and -2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices FEBS Letters 1991 285 1 111 114
43. Strohmeyer R., Ramirez M., Cole G. J., Mueller K., Rogers J., Association of factor H of the alternative pathway of complement with agrin and complement receptor 3 in the Alzheimer's disease brain Journal of Neuroimmunology 2002 131 1-2 135 146
44. Maes O. C., Kravitz S., Mawal Y., Su H., Liberman A., Mehindate K., Berlin D., Sahlas D. J., Chertkow H. M., Bergman H., Melmed C., Schipper H. M., Characterization of 1-antitrypsin as a heme oxygenase-1 suppressor in Alzheimer plasma Neurobiology of Disease 2006 24 1 89 100
45. Matsubara E., Hirai S., Amari M., Shoji M., Yamaguchi H., Okamoto K., Ishiguro K., Harigaya Y., Wakabayashi K., 1-antichymotrypsin as a possible biochemical marker for Alzheimer-type dementia Annals of Neurology 1990 28 4 561 567
46. Liebermann J., Schleissner L., Tachiki K. H., Kling A. S., Serum 1-antichymotrypsin level as a marker for Alzheimer-type dementia Neurobiology of Aging 1995 16 5 747 753
47. Merched A., Xia Y., Visvikis S., Serot J. M., Siest G., Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer's disease Neurobiology of Aging 2000 21 1 27 30
48. Irizarry M. C., Biomarkers of Alzheimer Disease in Plasma NeuroRx 2004 1 2 226 234
49. Graff-Radford N. R., Crook J. E., Lucas J., Boeve B. F., Knopman D. S., Ivnik R. J., Smith G. E., Younkin L. H., Petersen R. C., Younkin S. G., Association of low plasma A 42/A 40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease Archives of Neurology 2007 64 3 354 362
50. Ray S., Britschgi M., Herbert C., Takeda-Uchimura Y., Boxer A., Blennow K., Friedman L. F., Galasko D. R., Jutel M., Karydas A., Kaye J. A., Leszek J., Miller B. L., Minthon L., Quinn J. F., Rabinovici G. D., Robinson W. H., Sabbagh M. N., So Y. T., Sparks D. L., Tabaton M., Tinklenberg J., Yesavage J. A., Tibshirani R., Wyss-Coray T., Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins Nature Medicine 2007 13 11 1359 1362
51. Ghanbari H., Ghanbari K., Beheshti I., Munzar M., Vasauskas A., Averback P., Biochemical assay for AD7C-NTP in urine as an Alzheimer's disease marker Journal of Clinical Laboratory Analysis 1998 12 5 285 288
52. Levy S., McConville M., Lazaro G. A., Averback P., Competitive ELISA studies of neural thread protein in urine in Alzheimer's disease Journal of Clinical Laboratory Analysis 2007 21 1 24 33
53. de la Monte S. M., Wands J. R., The AD7c-ntp neuronal thread protein biomarker for detecting Alzheimer's disease Frontiers in Bioscience 2002 7 d989 996
54. Pratic D., Clark C. M., Lee V. M.-Y., Trojanowski J. Q., Rokach J., Fitzgerald G. A., Increased 8,12-iso-iPF(2 )-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity Annals of Neurology 2000 48 5 809 812
55. Pratic D., Clark C. M., Liun F., Lee V. Y.-M., Trojanowski J. Q., Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease Archives of Neurology 2002 59 6 972 976
56. Tuppo E. E., Forman L. J., Spur B. W., Chan-Ting R. E., Chopra A., Cavalieri T. A., Sign of lipid peroxidation as measured in the urine of patients with probable Alzheimer's disease Brain Research Bulletin 2001 54 5 565 568
57. Bohnstedt K. C., Karlberg B., Wahlund L.-O., Jnhagen M. E., Basun H., Schmidt S., Determination of isoprostanes in urine samples from Alzheimer patients using porous graphitic carbon liquid chromatography-tandem mass spectrometry Journal of Chromatography B 2003 796 1 11 19
58. Montine T. J., Shinobu L., Montine K. S., Roberts L. J. II, Kowall N. W., Beal M. F., Morrow J. D., No difference in plasma or urinary F2-isoprostanes among patients with Huntington's disease or Alzheimer's disease and controls Annals of Neurology 2000 48 6 950
59. Thongboonkerd V., Practical points in urinary proteomics Journal of Proteome Research 2007 6 10 3881 3890
60. Formichi P., Battisti C., Radi E., Federico A., Cerebrospinal fluid tau, A, and phosphorylated tau protein for the diagnosis of Alzheimer's disease Journal of Cellular Physiology 2006 208 1 39 46
61. Craig-Schapiro R., Fagan A. M., Holtzman D. M., Biomarkers of Alzheimer's disease Neurobiology of Disease 2009 35 2 128 140
62. Citron M., Diehl T. S., Gordon G., Biere A. L., Seubert P., Selkoe D. J., Evidence that the 42- and 40-amino acid forms of amyloid protein are generated from the -amyloid precursor protein by different protease activities Proceedings of the National Academy of Sciences of the United States of America 1996 93 23 13170 13175
63. Van Nostrand W. E., Wagner S. L., Shankle W. R., Farrow J. S., Dick M., Rozemuller J. M., Kuiper M. A., Wolters E. C., Zimmerman J., Cotman C. W., Cunningham D. D., Decreased levels of soluble amyloid -protein precursor in cerebrospinal fluid of live Alzheimer disease patients Proceedings of the National Academy of Sciences of the United States of America 1992 89 7 2551 2555
64. Roher A. E., Lowenson J. D., Clarke S., Woods A. S., Cotter R. J., Gowing E., Ball M. J., -Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease Proceedings of the National Academy of Sciences of the United States of America 1993 90 22 10836 10840
65. Lannfelt L., Basun H., Vigo-Pelfrey C., Wahlund L.-O., Winblad B., Lieberburg I., Schenk D., Amyloid -peptide in cerebrospinal fluid in individuals with the Swedish Alzheimer amyloid precursor protein mutation Neuroscience Letters 1995 199 3 203 206
66. Andreasen N., Hesse C., Davidsson P., Minthon L., Wallin A., Winblad B., Vanderstichele H., Vanmechelen E., Blennow K., Cerebrospinal fluid -amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease Archives of Neurology 1999 56 6 673 680
67. Galasko D., Chang L., Motter R., Clark C. M., Kaye J., Knopman D., Thomas R., Kholodenko D., Schenk D., Lieberburg I., Miller B., Green R., Basherad R., Kertiles L., Boss M. A., Seubert P., High cerebrospinal fluid tau and low amyloid 42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype Archives of Neurology 1998 55 7 937 945
68. Hampel H., Teipel S. J., Fuchsberger T., Andreasen N., Wiltfang J., Otto M., Shen Y., Dodel R., Du Y., Farlow M., Mller H.-J., Blennow K., Buerger K., Value of CSF -amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment Molecular Psychiatry 2004 9 7 705 710
69. Lewczuk P., Esselmann H., Otto M., Maler J. M., Henkel A. W., Henkel M. K., Eikenberg O., Antz C., Krause W.-R., Reulbach U., Kornhuber J., Wiltfang J., Neurochemical diagnosis of Alzheimer's dementia by CSF A 42, A 42/A 40 ratio and total tau Neurobiology of Aging 2004 25 3 273 281
70. Mulder C., Schoonenboom S. N. M., Wahlund L.-O., Scheltens PH., Van Kamp G. J., Veerhuis R., Hack C. E., Blomberg M., Schutgens R. B. H., Eikelenboom P., CSF markers related to pathogenetic mechanisms in Alzheimer's disease Journal of Neural Transmission 2002 109 12 1491 1498
71. Jensen M., Schrder J., Blomberg M., Engvall B., Pantel J., Ida N., Basun H., Wahlund L.-O., Werle E., Jauss M., Beyreuther K., Lannfelt L., Hartmann T., Cerebrospinal fluid A 42 is increased early in sporadic Alzheimer's disease and declines with disease progression Annals of Neurology 1999 45 4 504 511
72. Csernansky J. G., Miller J. P., McKeel D., Morris J. C., Relationships among cerebrospinal fluid biomarkers in dementia of the Alzheimer type Alzheimer Disease and Associated Disorders 2002 16 3 144 149
73. DeMattos R. B., Bales K. R., Parsadanian M., O'Dell M. A., Foss E. M., Paul S. M., Holtzman D. M., Plaque-associated disruption of CSF and plasma amyloid- (A ) equilibrium in a mouse model of Alzheimer's disease Journal of Neurochemistry 2002 81 2 229 236
74. Hulstaert F., Blennow K., Ivanoiu A., Schoonderwaldt H. C., Riemenschneider M., De Deyn P. P., Bancher C., Cras P., Wiltfang J., Mehta P. D., Iqbal K., Pottel H., Vanmechelen E., Vanderstichele H., Improved discrimination of AD patients using -amyloid (1-42) and tau levels in CSF Neurology 1999 52 8 1555 1562
75. Riemenschneider M., Wagenpfeil S., Diehl J., Lautenschlager N., Theml T., Heldmann B., Drzezga A., Jahn T., Frstl H., Kurz A., Tau and A 42 protein in CSF of patients with frontotemporal degeneration Neurology 2002 58 11 1622 1628
76. Sjgren M., Minthon L., Davidsson P., Granrus A.-K., Clarberg A., Vanderstichele H., Vanmechelen E., Wallin A., Blennow K., CSF levels of tau, -amyloid1-42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging Journal of Neural Transmission 2000 107 5 563 579
77. Cairns N. J., Ikonomovic M. D., Benzinger T., Absence of Pittsburgh compound B detection of cerebral amyloid in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report Archives of Neurology 2009 66 12 1557 1562
78. Hansson O., Zetterberg H., Buchhave P., Andreasson U., Londos E., Minthon L., Blennow K., Prediction of Alzheimer's disease using the CSF A 42/A 40 ratio in patients with mild cognitive impairment Dementia and Geriatric Cognitive Disorders 2007 23 5 316 320
79. Lewczuk P., Esselmann H., Meyer M., Wollscheid V., Neumann M., Otto M., Maler J. M., Rther E., Kornhuber J., Wiltfang J., The amyloid- (A ) peptide pattern in cerebrospinal fluid in Alzheimer's disease: evidence of a novel carboxyterminally elongated A peptide Rapid Communications in Mass Spectrometry 2003 17 12 1291 1296
80. Schoonenboom N. S., Mulder C., Van Kamp G. J., Mehta S. P., Scheltens P., Blankenstein M. A., Mehta P. D., Amyloid 38, 40, and 42 species in cerebrospinal fluid: more of the same? Annals of Neurology 2005 58 1 139 142
81. Portelius E., Price E., Brinkmalm G., Stiteler M., Olsson M., Persson R., Westman-Brinkmalm A., Zetterberg H., Simon A. J., Blennow K., A novel pathway for amyloid precursor protein processing. Neurobiology of Aging. In press
82. Portelius E., Zetterberg H., Andreasson U., Brinkmalm G., Andreasen N., Wallin A., Westman-Brinkmalm A., Blennow K., An Alzheimer's disease-specific -amyloid fragment signature in cerebrospinal fluid Neuroscience Letters 2006 409 3 215 219
83. Lewis J., Dickson D. W., Lin W.-L., Chisholm L., Corral A., Jones G., Yen S.-H., Sahara N., Skipper L., Yager D., Eckman C., Hardy J., Hutton M., McGowan E., Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP Science 2001 293 5534 1487 1491
84. Mandelkow E.-M., Mandelkow E., Tau in Alzheimer's disease Trends in Cell Biology 1998 8 11 425 427
85. Goedert M., Tau protein and the neurofibrillary pathology of Alzheimer's disease Trends in Neurosciences 1993 16 11 460 465
86. Iqbal K., Alonso A. D. C., Gong C.-X., Khatoon S., Pei J.-J., Wang J. Z., Grundke-Iqbal I., Mechanisms of neurofibrillary degeneration and the formation of neurofibrillary tangles Journal of Neural Transmission, Supplement 1998 53 169 180
87. Vandermeeren M., Mercken M., Vanmechelen E., Six J., Van de Voorde A., Martin J.-J., Cras P., Detection of proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay Journal of Neurochemistry 1993 61 5 1828 1834
88. Morikawa Y.-I., Arai H., Matsushita S., Kato M., Higuchi S., Miura M., Kawakami H., Higuchi M., Okamura N., Tashiro M., Matsui T., Sasaki H., Cerebrospinal fluid tau protein levels in demented and nondemented alcoholics Alcoholism: Clinical and Experimental Research 1999 23 4 575 577
89. Hu Y. Y., He S. S., Wang X., Duan Q. H., Grundke-Iqbal I., Iqbal K., Wang J., Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients: an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay American Journal of Pathology 2002 160 4 1269 1278
90. Hampel H., Buerger K., Zinkowski R., Teipel S. J., Goernitz A., Andreasen N., Sjoegren M., DeBernardis J., Kerkman D., Ishiguro K., Ohno H., Vanmechelen E., Vanderstichele H., McCulloch C., Mller H.-J., Davies P., Blennow K., Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study Archives of General Psychiatry 2004 61 1 95 102
91. Koopman K., Le Bastard N., Martin J.-J., Nagels G., De Deyn P. P., Engelborghs S., Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau181P Neurochemistry International 2009 55 4 214 218
92. Li G., Sokal I., Quinn J. F., Leverenz J. B., Brodey M., Schellenberg G. D., Kaye J. A., Raskind M. A., Zhang J., Peskind E. R., Montine T. J., CSF tau/A 42 ratio for increased risk of mild cognitive impairment: a follow-up study Neurology 2007 69 7 631 639
93. Maji S. K., Ogorzalek Loo R. R., Inayathullah M., Spring S. M., Vollers S. S., Condron M. M., Bitan G., Loo J. A., Teplow D. B., Amino acid position-specific contributions to amyloid -protein oligomerization The Journal of Biological Chemistry 2009 284 35 23580 23591
94. Kirkitadze M. D., Bitan G., Teplow D. B., Paradigm shifts in Alzheimer's disease and other neurodegenerative disorders: the emerging role of oligomeric assemblies Journal of Neuroscience Research 2002 69 5 567 577
95. Klein W. L., Stine W. B. Jr., Teplow D. B., Small assemblies of unmodified amyloid -protein are the proximate neurotoxin in Alzheimer's disease Neurobiology of Aging 2004 25 5 569 580
96. Walsh D. M., Selkoe D. J., A oligomersa decade of discovery Journal of Neurochemistry 2007 101 5 1172 1184
97. Hardy J., Selkoe D. J., The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics Science 2002 297 5580 353 356
98. Walsh D. M., Klyubin I., Fadeeva J. V., Cullen W. K., Anwyl R., Wolfe M. S., Rowan M. J., Selkoe D. J., Naturally secreted oligomers of amyloid protein potently inhibit hippocampal long-term potentiation in vivo Nature 2002 416 6880 535 539
99. Oda T., Wals P., Osterburg H. H., Johnson S. A., Pasinetti G. M., Morgan T. E., Rozovsky I., Stine W. B., Snyder S. W., Holzman T. F., Krafft G. A., Finch C. E., Clusterin (apoJ) alters the aggregation of amyloid -peptide (A 1-42) and forms slowly sedimenting A complexes that cause oxidative stress Experimental Neurology 1995 136 1 22 31
100. Lambert M. P., Barlow A. K., Chromy B. A., Edwards C., Freed R., Liosatos M., Morgan T. E., Rozovsky I., Trommer B., Viola K. L., Wals P., Zhang C., Finch C. E., Krafft G. A., Klein W. L., Diffusible, nonfibrillar ligands derived from A 1-42 are potent central nervous system neurotoxins Proceedings of the National Academy of Sciences of the United States of America 1998 95 11 6448 6453
101. Walsh D. M., Hartley D. M., Kusumoto Y., Fezoui Y., Condron M. M., Lomakin A., Benedek G. B., Selkoe D. J., Teplow D. B., Amyloid -protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates The Journal of Biological Chemistry 1999 274 36 25945 25952
102. Hartley D. M., Walsh D. M., Ye C. P., Diehl T., Vasquez S., Vassilev P. M., Teplow D. B., Selkoe D. J., Protofibrillar intermediates of amyloid -protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons Journal of Neuroscience 1999 19 20 8876 8884
103. Chen Q.-S., Kagan B. L., Hirakura Y., Xie C.-W., Impairment of hippocampal long-term potentiation by Alzheimer amyloid -peptides Journal of Neuroscience Research 2000 60 1 65 72
104. Nalbantoglu J., Tirado-Santiago G., Lahsani A., Poirier J., Goncalves O., Verge G., Momoli F., Welner S. A., Massicotte G., Julien J.-P., Shapiro M. L., Impaired learning and LTP in mice expressing the carboxy terminus of the Alzheimer amyloid precursor protein Nature 1997 387 6632 500 505
105. Dahlgren K. N., Manelli A. M., Blaine Stine W. Jr., Baker L. K., Krafft G. A., Ladu M. J., Oligomeric and fibrillar species of amyloid- peptides differentially affect neuronal viability The Journal of Biological Chemistry 2002 277 35 32046 32053
106. Klyubin I., Walsh D. M., Cullen W. K., Fadeeva J. V., Anwyl R., Selkoe D. J., Rowan M. J., Soluble Arctic amyloid protein inhibits hippocampal long-term potentiation in vivo European Journal of Neuroscience 2004 19 10 2839 2846
107. Wang H.-W., Pasternak J. F., Kuo H., Ristic H., Lambert M. P., Chromy B., Viola K. L., Klein W. L., Stine W. B., Krafft G. A., Trommer B. L., Soluble oligomers of amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus Brain Research 2002 924 2 133 140
108. Cleary J. P., Walsh D. M., Hofmeister J. J., Shankar G. M., Kuskowski M. A., Selkoe D. J., Ashe K. H., Natural oligomers of the amyloid- protein specifically disrupt cognitive function Nature Neuroscience 2005 8 1 79 84
109. De Felice F. G., Vieira M. N. N., Meirelles M. N. L., Morozova-Roche L. A., Dobson C. M., Ferreira S. T., Formation of amyloid aggregates from human lysozyme and its disease-associated variants using hydrostatic pressure FASEB Journal 2004 18 10 1099 1101
110. Head E., Pop V., Vasilevko V., A two-year study with fibrillar beta-amyloid (Abeta) immunization in aged canines: effects on cognitive function and brain Abeta The Journal of Neuroscience 2008 28 14 3555 3566
111. White J. A., Manelli A. M., Holmberg K. H., Van Eldik L. J., LaDu M. J., Differential effects of oligomeric and fibrillar amyloid- 1-42 on astrocyte-mediated inflammation Neurobiology of Disease 2005 18 3 459 465
112. Demuro A., Mina E., Kayed R., Milton S. C., Parker I., Glabe C. G., Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers The Journal of Biological Chemistry 2005 280 17 17294 17300
113. Chong Y.H., Shin Y. J., Lee E.O., ERK1/2 activation mediates A oligomer-induced neurotoxicity via caspase-3 activation and Tau cleavage in rat organotypic hippocampal slice cultures The Journal of Biological Chemistry 2006 281 29 20315 20325
114. Lesn S., Ming T. K., Kotilinek L., Kayed R., Glabe C. G., Yang A., Gallagher M., Ashe K. H., A specific amyloid- protein assembly in the brain impairs memory Nature 2006 440 7082 352 357
115. Townsend M., Shankar G. M., Mehta T., Walsh D. M., Selkoe D. J., Effects of secreted oligomers of amyloid -protein on hippocampal synaptic plasticity: a potent role for trimers Journal of Physiology 2006 572 2 477 492
116. Kuo Y.-M., Emmerling M. R., Vigo-Pelfrey C., Kasunic T. C., Kirkpatrick J. B., Murdoch G. H., Ball M. J., Roher A. E., Water-soluble A (N-40, N-42) oligomers in normal and Alzheimer disease brains The Journal of Biological Chemistry 1996 271 8 4077 4081
117. Kayed R., Head E., Thompson J. L., McIntire T. M., Milton S. C., Cotman C. W., Glabel C. G., Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis Science 2003 300 5618 486 489
118. Gong Y., Chang L., Viola K. L., Lacor P. N., Lambert M. P., Finch C. E., Krafft G. A., Klein W. L., Alzheimer's disease-affected brain: presence of oligomeric A ligands (ADDLs) suggests a molecular basis for reversible memory loss Proceedings of the National Academy of Sciences of the United States of America 2003 100 18 10417 10422
119. Pitschke M., Prior R., Haupt M., Riesner D., Detection of single amyloid -protein aggregates in the cerebrospinal fluid of Alzheirner's patients by fluorescence correlation spectroscopy Nature Medicine 1998 4 7 832 834
120. Georganopoulou D. G., Chang L., Nam J.-M., Thaxton C. S., Mufson E. J., Klein W. L., Mirkin C. A., Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease Proceedings of the National Academy of Sciences of the United States of America 2005 102 7 2273 2276
121. Lee J.-M., Blennow K., Andreasen N., Laterza O., Modur V., Olander J., Gao F., Ohlendorf M., Ladenson J. H., The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients Clinical Chemistry 2008 54 10 1617 1623
122. Rosengren L. E., Karlsson J.-E., Sjgren M., Blennow K., Wallin A., Neurofilament protein levels in CSF are increased in dementia Neurology 1999 52 5 1090 1093
123. Sjgren M., Davidsson P., Gottfries J., Vanderstichele H., Edman A., Vanmechelen E., Wallin A., Blennow K., The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer's disease, reflecting a common pathophysiological process Dementia and Geriatric Cognitive Disorders 2001 12 4 257 264
124. Pratic D., Alzheimer's disease and oxygen radicals: new insights Biochemical Pharmacology 2002 63 4 563 567
125. Montine T. J., Beal M. F., Cudkowicz M. E., O'Donnell H., Margolin R. A., McFarland L., Bachrach A. F., Zackert W. E., Roberts L. J., Morrow J. D., Increased CSF F2-isoprostane concentration in probable AD Neurology 1999 52 3 562 565
126. Pratic D., Lee V. M.-Y., Trojanowski J. Q., Rokach J., Fitzgerald G. A., Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo FASEB Journal 1998 12 15 1777 1783
127. Montine T. J., Kaye J. A., Montine K. S., Cerebrospinal fluid abeta42, tau, and f2-isoprostane concentrations in patients with Alzheimer disease, other dementias, and in age-matched controls Archives of Pathology Laboratory Medicine 2001 125 4 510 512
128. Harigaya Y., Shoji M., Nakamura T., Matsubara E., Hosoda K., Hirai S., Alpha 1-antichymotrypsin level in cerebrospinal fluid is closely associated with late onset Alzheimer's disease Internal Medicine 1995 34 6 481 484
129. Pirttila T., Mehta P. D., Frey H., Wisniewski H. M., 1-Antichymotrypsin and IL-1 are not increased in CSF or serum in Alzheimer's disease Neurobiology of Aging 1994 15 3 313 317
130. Blum-Degena D., Mller T., Kuhn W., Gerlach M., Przuntek H., Riederer P., Interleukin-1 and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients Neuroscience Letters 1995 202 1-2 17 20
131. Jia J. P., Meng R., Sun Y. X., Sun W. J., Ji X. M., Jia L. F., Cerebrospinal fluid tau, A 1-42 and inflammatory cytokines in patients with Alzheimer's disease and vascular dementia Neuroscience Letters 2005 383 1-2 12 16
132. Martnez M., Fernndez-Vivancos E., Frank A., De La Fuente M., Hernanz A., Increased cerebrospinal fluid Fas (Apo-1) levels in Alzheimer's disease: relationship with IL-6 concentrations Brain Research 2000 869 1-2 216 219
133. Yamada K., Kono K., Umegaki H., Yamada K., Iguchi A., Fukatsu T., Nakashima N., Nishiwaki H., Shimada Y., Sugita Y., Yamamoto T., Hasegawa T., Nabeshima T., Decreased interleukin-6 level in the cerebrospinal fluid of patients with Alzheimer-type dementia Neuroscience Letters 1995 186 2-3 219 221
134. Engelborghs S., De Brabander M., De Cre J., D'Hooge R., Geerts H., Verhaegen H., De Deyn P. P., Unchanged levels of interleukins, neopterin, interferon- and tumor necrosis factor- in cerebrospinal fluid of patients with dementia of the Alzheimer type Neurochemistry International 1999 34 6 523 530
135. Mrz P., Heese K., Hock C., Golombowski S., Mller-Spahn F., Rose-John S., Otten U., Interleukin-6 (IL-6) and soluble forms of IL-6 receptors are not altered in cerebrospinal fluid of Alzheimer's disease patients Neuroscience Letters 1997 239 1 29 32
136. Tarkowski E., Blennow K., Wallin A., Tarkowski A., Intracerebral production of tumor necrosis factor-, a local neuroprotective agent, in Alzheimer disease and vascular dementia Journal of Clinical Immunology 1999 19 4 223 230
137. Teunissen C. E., de Vente J., Steinbusch H. W. M., De Bruijn C., Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid Neurobiology of Aging 2002 23 4 485 508
138. Flirski M., Sobow T., Biochemical markers and risk factors of Alzheimer's disease Current Alzheimer Research 2005 2 1 47 64
139. Dubois B., Feldman H. H., Jacova C., DeKosky S. T., Barberger-Gateau P., Cummings J., Delacourte A., Galasko D., Gauthier S., Jicha G., Meguro K., O'Brien J., Pasquier F., Robert P., Rossor M., Salloway S., Stern Y., Visser P. J., Scheltens P., Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria Lancet Neurology 2007 6 8 734 746